PE20010685A1 - Composicion que comprende un polipeptido antagonista del receptor de interleuquina 1 y una diarilsulfonilurea como inhibidor del procesamiento y la liberacion de il-1 - Google Patents
Composicion que comprende un polipeptido antagonista del receptor de interleuquina 1 y una diarilsulfonilurea como inhibidor del procesamiento y la liberacion de il-1Info
- Publication number
- PE20010685A1 PE20010685A1 PE2000000942A PE0009422000A PE20010685A1 PE 20010685 A1 PE20010685 A1 PE 20010685A1 PE 2000000942 A PE2000000942 A PE 2000000942A PE 0009422000 A PE0009422000 A PE 0009422000A PE 20010685 A1 PE20010685 A1 PE 20010685A1
- Authority
- PE
- Peru
- Prior art keywords
- interleuquin
- release
- processing
- urea
- hydroxy
- Prior art date
Links
- 108010002352 Interleukin-1 Proteins 0.000 title abstract 2
- 229920001184 polypeptide Polymers 0.000 title abstract 2
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 2
- 102000004196 processed proteins & peptides Human genes 0.000 title abstract 2
- 239000003112 inhibitor Substances 0.000 title 1
- 239000002464 receptor antagonist Substances 0.000 title 1
- 229940044551 receptor antagonist Drugs 0.000 title 1
- -1 CYANE Chemical class 0.000 abstract 5
- 239000004202 carbamide Substances 0.000 abstract 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical class CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 abstract 1
- 150000001413 amino acids Chemical class 0.000 abstract 1
- 239000005557 antagonist Substances 0.000 abstract 1
- 208000006673 asthma Diseases 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 229910052736 halogen Inorganic materials 0.000 abstract 1
- 150000002367 halogens Chemical class 0.000 abstract 1
- 208000027866 inflammatory disease Diseases 0.000 abstract 1
- 102000009634 interleukin-1 receptor antagonist activity proteins Human genes 0.000 abstract 1
- 108040001669 interleukin-1 receptor antagonist activity proteins Proteins 0.000 abstract 1
- 230000004770 neurodegeneration Effects 0.000 abstract 1
- 229910052757 nitrogen Inorganic materials 0.000 abstract 1
- 201000008482 osteoarthritis Diseases 0.000 abstract 1
- 229910052760 oxygen Inorganic materials 0.000 abstract 1
- 206010039073 rheumatoid arthritis Diseases 0.000 abstract 1
- 229910052717 sulfur Inorganic materials 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/64—Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Rheumatology (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pain & Pain Management (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
SE REFIERE A USO DE UNA COMPOSICION QUE COMPRENDE: a)UN POLIPEPTIDO ANTAGONISTA DEL RECEPTOR DE INTERLEUQUINA 1 (IL-1ra), DE PREFERENCIA DE UNA SECUENCIA (ID SEQ N°2) DE 169 AMINOACIDOS; b)UN AGENTE NO ESTEROIDEO QUE INHIBE EL PROCESAMIENTO Y LA LIBERACION DE IL-1 TAL COMO DIARILSULFONILUREA R1-(O=)S(=O)-NH-C(=O)-NH-R2; DONDE R1 Y R2 SON UN GRUPO DE FORMULA II EN LA QUE LAS LINEAS --- REPRESENTAN DOBLES ENLACES OPCIONALES; n ES 0-3; A, B, D, E Y G SON O, S, N, CR5R6; R5 Y R6 SON H, ALQUILO C1-C6, HALOGENO, CIANO, AMINO, OH, ENTRE OTROS, SIENDO COMPUESTOS SELECCIONADOS 1-(1,2,3,5,6,7-HEXAHIDRO-s-INDACEN-4-IL)-3-[4-(1-HIDROXI-1-METIL-ETIL)-FURANO-2-SULFONIL]-UREA, 1-(2,6-DIISOPROPIL-FENIL)-3-[4-(1-HIDROXI-1-METIL-ETIL-FURANO-2-SULFONIL]-UREA, 1-(4-CLORO-2,6-DIISOPROPIL-FENIL)-3-[3-(HIDROXI-1-METIL-ETIL)-BENCENOSULFONIL]-UREA, ENTRE OTROS. LA COMPOSICION PUEDE SER UTIL PARA EL TRATAMIENTO DE TRASTORNOS INFLAMATORIOS TAL COMO ARTRITIS REUMATOIDE, OSTEOARTRITIS, ASMA, NEURODEGENERACION, ENTRE OTROS
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US15401099P | 1999-09-14 | 1999-09-14 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20010685A1 true PE20010685A1 (es) | 2001-07-03 |
Family
ID=22549650
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2000000942A PE20010685A1 (es) | 1999-09-14 | 2000-09-12 | Composicion que comprende un polipeptido antagonista del receptor de interleuquina 1 y una diarilsulfonilurea como inhibidor del procesamiento y la liberacion de il-1 |
Country Status (13)
| Country | Link |
|---|---|
| EP (1) | EP1214087A1 (es) |
| JP (1) | JP2003509378A (es) |
| AR (1) | AR033650A1 (es) |
| AU (1) | AU6464400A (es) |
| BR (1) | BR0014003A (es) |
| CA (1) | CA2383026A1 (es) |
| CO (1) | CO5190701A1 (es) |
| EC (1) | ECSP003652A (es) |
| GT (1) | GT200000155A (es) |
| PA (1) | PA8502901A1 (es) |
| PE (1) | PE20010685A1 (es) |
| TN (1) | TNSN00183A1 (es) |
| WO (1) | WO2001019390A1 (es) |
Families Citing this family (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2005231822B2 (en) | 2004-04-02 | 2011-07-21 | Swedish Orphan Biovitrum Ab (Publ) | Methods of reducing aggregation of IL-1ra |
| WO2008129288A2 (en) * | 2007-04-19 | 2008-10-30 | Boehringer Ingelheim International Gmbh | Disulfonamides useful in the treatment of inflammation |
| ME03737B (me) * | 2015-02-16 | 2021-01-20 | Univ Queensland | Sulfoniluree i srodna jedinjenja i njihova upotreba |
| BR112018016671A2 (pt) | 2016-02-16 | 2018-12-26 | The University Of Queensland | sulfonilureias e compostos relacionados e uso do mesmo |
| EP3445756B1 (en) | 2016-04-18 | 2022-07-06 | Novartis AG | Compounds and compositions for treating conditions associated with nlrp activity |
| UA126675C2 (uk) | 2017-01-23 | 2023-01-11 | Дженентек, Інк. | Хімічні сполуки як інгібітори активності інтерлейкіну-1 |
| BR112019024831A2 (pt) | 2017-05-24 | 2020-06-09 | The University Of Queensland | composto, sal, solvato ou pró-droga, composição farmacêutica, método de tratamento ou prevenção de uma doença, método para inibir o nlrp3 |
| US11236045B2 (en) | 2017-06-09 | 2022-02-01 | Cadila Healthcare Limited | Substituted sulfoximine compounds |
| US11370776B2 (en) | 2017-07-07 | 2022-06-28 | Inflazome Limited | Sulfonylureas and sulfonylthioureas as NLRP3 inhibitors |
| CN120647572A (zh) | 2017-07-07 | 2025-09-16 | 英夫拉索姆有限公司 | 新颖磺酰胺羧酰胺化合物 |
| SI3658539T1 (sl) | 2017-07-24 | 2024-06-28 | Novartis Ag | Spojine in sestavki za zdravljenje stanj, povezanih z delovanjem nlrp |
| AU2018317800A1 (en) | 2017-08-15 | 2020-02-13 | Inflazome Limited | Novel sulfonamide carboxamide compounds |
| US11542255B2 (en) | 2017-08-15 | 2023-01-03 | Inflazome Limited | Sulfonylureas and sulfonylthioureas as NLRP3 inhibitors |
| EP3668840A1 (en) | 2017-08-15 | 2020-06-24 | Inflazome Limited | Novel sulfonamide carboxamide compounds |
| WO2019034693A1 (en) | 2017-08-15 | 2019-02-21 | Inflazome Limited | SULFONYLURATES AND SULFONYLTHIOURES AS INHIBITORS OF NLRP3 |
| AU2018317798A1 (en) * | 2017-08-15 | 2020-02-13 | Inflazome Limited | Sulfonylureas and sulfonylthioureas as NLRP |
| WO2019043610A1 (en) | 2017-08-31 | 2019-03-07 | Cadila Healthcare Limited | NEW SUBSTITUTED SULFONYLUREA DERIVATIVES |
| EP3692020A1 (en) | 2017-10-03 | 2020-08-12 | Inflazome Limited | Novel compounds |
| JP2021502364A (ja) | 2017-11-09 | 2021-01-28 | インフレイゾーム リミテッド | 新規なスルホンアミドカルボキサミド化合物 |
| US12221434B2 (en) | 2017-11-09 | 2025-02-11 | Inflazome Limited | Sulfonamide carboxamide compounds |
| US12030879B2 (en) | 2018-03-02 | 2024-07-09 | Inflazome Limited | Sulfonyl acetamides as NLRP3 inhibitors |
| US11884645B2 (en) | 2018-03-02 | 2024-01-30 | Inflazome Limited | Sulfonyl acetamides as NLRP3 inhibitors |
| US11905252B2 (en) | 2018-03-02 | 2024-02-20 | Inflazome Limited | Compounds |
| EP3759102A1 (en) | 2018-03-02 | 2021-01-06 | Inflazome Limited | Novel compounds |
| WO2019166633A1 (en) | 2018-03-02 | 2019-09-06 | Inflazome Limited | Sulfonamide derivates as nlrp3 inhibitors |
| US11530200B2 (en) | 2018-03-02 | 2022-12-20 | Inflazome Limited | Compounds |
| GB201806578D0 (en) * | 2018-04-23 | 2018-06-06 | Inflazome Ltd | Novel compound |
| EP3817817A1 (en) | 2018-07-03 | 2021-05-12 | Novartis AG | Nlrp modulators |
| CR20210022A (es) | 2018-07-20 | 2021-02-18 | Hoffmann La Roche | Compuestos de sulfonimidamida como inhibidores de la actividad de interleucina-1 |
| CN112437683A (zh) | 2018-07-20 | 2021-03-02 | 豪夫迈·罗氏有限公司 | 用作白细胞介素-1 活性抑制剂的磺酰脲类化合物 |
| EP3836917A1 (en) | 2018-08-15 | 2021-06-23 | Inflazome Limited | Novel sulfonamideurea compounds |
| WO2020086732A1 (en) | 2018-10-24 | 2020-04-30 | Novartis Inflammasome Research, Inc. | Compounds and compositions for treating conditions associated with nlrp activity |
| EA202191968A1 (ru) | 2019-01-14 | 2021-11-16 | Кадила Хелзкэр Лимитед | Новые замещенные производные сульфонилмочевины |
| WO2021237891A1 (en) * | 2020-05-25 | 2021-12-02 | Beijing Vdjbio Co., Ltd. | An interleukin-1 receptor antagonist and a fusion protein containing the same |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5874424A (en) * | 1995-12-20 | 1999-02-23 | Vertex Pharmaceuticals Incorporated | Inhibitors of interleukin-1β converting enzyme |
| EA001803B1 (ru) * | 1997-01-29 | 2001-08-27 | Пфайзер Инк. | Производные сульфонилмочевины и их применение для контроля активности интерлейкина-1 |
| US6015790A (en) * | 1997-10-06 | 2000-01-18 | Basf Aktiengesellschaft | Methods and compositions for treating rheumatoid arthritis |
| EP0987552A3 (en) * | 1998-08-31 | 2000-06-07 | Pfizer Products Inc. | Diarylsulfonylurea binding proteins |
-
2000
- 2000-08-28 JP JP2001523022A patent/JP2003509378A/ja active Pending
- 2000-08-28 WO PCT/IB2000/001192 patent/WO2001019390A1/en not_active Ceased
- 2000-08-28 AU AU64644/00A patent/AU6464400A/en not_active Abandoned
- 2000-08-28 CA CA002383026A patent/CA2383026A1/en not_active Abandoned
- 2000-08-28 BR BR0014003-1A patent/BR0014003A/pt not_active IP Right Cessation
- 2000-08-28 EP EP00951799A patent/EP1214087A1/en not_active Withdrawn
- 2000-09-05 CO CO00066883A patent/CO5190701A1/es not_active Application Discontinuation
- 2000-09-11 PA PA20008502901A patent/PA8502901A1/es unknown
- 2000-09-12 AR ARP000104779A patent/AR033650A1/es not_active Application Discontinuation
- 2000-09-12 EC EC2000003652A patent/ECSP003652A/es unknown
- 2000-09-12 PE PE2000000942A patent/PE20010685A1/es not_active Application Discontinuation
- 2000-09-13 TN TNTNSN00183A patent/TNSN00183A1/fr unknown
- 2000-09-14 GT GT200000155A patent/GT200000155A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP1214087A1 (en) | 2002-06-19 |
| BR0014003A (pt) | 2002-05-21 |
| TNSN00183A1 (fr) | 2005-11-10 |
| ECSP003652A (es) | 2002-04-23 |
| PA8502901A1 (es) | 2002-02-21 |
| CA2383026A1 (en) | 2001-03-22 |
| GT200000155A (es) | 2002-03-08 |
| WO2001019390A1 (en) | 2001-03-22 |
| AU6464400A (en) | 2001-04-17 |
| JP2003509378A (ja) | 2003-03-11 |
| CO5190701A1 (es) | 2002-08-29 |
| AR033650A1 (es) | 2004-01-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20010685A1 (es) | Composicion que comprende un polipeptido antagonista del receptor de interleuquina 1 y una diarilsulfonilurea como inhibidor del procesamiento y la liberacion de il-1 | |
| PE20040840A1 (es) | Derivados de 4-oxoquinolina como inhibidores de la integrasa del vih | |
| ES2161231T3 (es) | Compuestos heterociclicos como antagonistas de bradiquinina. | |
| ATE420644T1 (de) | Kondensierte azabicyclischeverbindungen als inhibitoren des vanilloid-rezeptors 1 (vr1) | |
| DE602004012858D1 (de) | 2-aminobenzothiazole als cb1 rezeptor inverse agonisten | |
| MX2007013065A (es) | Derivados de dihidrobenzofurano y usos de los mismos. | |
| ATE469892T1 (de) | Substituierte 1h-dihydropyrazole, ihre herstellung und verwendung | |
| ATE290059T1 (de) | Tensidzusammensetzung enthaltend geminitenside und co-amphiphile, ihre herstellung und ihre verwendung | |
| BR0007595A (pt) | 4-(heterociclisulfonamido)-5-metóxi-6-(2-metoxifenó xi)-2-fenil-ou piridilpirimidinas como antagonistas de receptor de endotelina | |
| BRPI0413305A (pt) | compostos azabicìclicos fundidos que inibem o receptor de subtipo de receptor de vanilóide 1 (vr1) | |
| NO20063470L (no) | Tetrazolforbindelser og deres anvendelse av metabotrofe glutamatreseptorantagonister | |
| AR028824A1 (es) | Compuestos antagonistas npy-5 y su uso en la manufactura de medicamentos. | |
| DE602005020655D1 (de) | Carboxamid-spirolactam-cgrp-rezeptor-antagonisten | |
| DK1716152T3 (da) | Kondenserade heterocykliske forbindelser og deres anvendelse som metabotrope receptorantagonister til behandling af gastrointentinde lidelser | |
| ECSP045239A (es) | Composicion de ziprasidona y controles sinteticos | |
| EA200301073A1 (ru) | N-(2-арилэтил)бензиламины в качестве антагонистов 5-ht-рецептора | |
| BR0315644A (pt) | Piperazinil e diazapanil benzamidas e benzotioamidas | |
| ES2192264T3 (es) | Sal mesilato trihidrato de 5-(2-(4-(1,2-benzoisotiazol-3-il)-1-piperazinil)etil)-6-cloro-1,3-dihidro-2(1h)-indol-2-ona (=ziprasidona), su preparacion y su uso como antagonista de la dopamina. | |
| AR039489A1 (es) | Derivados de tetrahidropiranil ciclopentil tetrahidropiridopiridina, moduladores de actividad de receptores de citoquinas | |
| DE602006007556D1 (de) | Heteroarylsulfonylstilbene als 5-ht2a-antagonisten | |
| PE20060298A1 (es) | Derivados de acido carboxilico de bencimidazolona | |
| PE20030872A1 (es) | Composicion farmaceutica del agonista parcial de 5ht4 tegaserod | |
| SE0403171D0 (sv) | New compounds | |
| ATE374190T1 (de) | Tetrahydrochinazolinderivate als cfr-antagonisten | |
| PE83999A1 (es) | Azetidinas |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Refusal |